Navigation Links
Medical device, health professionals attend first national conference on value-driven engineering
Date:4/27/2012

spread acceptance of Value-driven Engineering principles in the biomedical device industry."

During the two day conference, attendees heard from:

  • Dr. Thomas Fogarty, Fogarty Institute for Innovation: "Value Collaboration between Physicians and Engineers"
  • Dr. Robert E. Litan, Ewing Marion Kauffman Foundation: "The Importance of Harnessing Bid Data with Respect to Defining the Value Equation"
  • Mike Hess, Medtronic Inc.: "What Value-driven Engineering Means to the Medical Device Industry"
  • Dr. William J. Heetderks, National Institutes of Health: "The Role of Federal Funding Agencies in the Adoption of Value-driven Engineering"
  • Dr. DeVon W. Griffin, NASA Glenn Research Center: "NASA's Need for Less Complex Medical Devices"
  • Megan Moynahan, U.S. Food and Drug Administration: "Regulatory Innovation Pathway"
  • Dr. Marc S. Penn, FACC, Summa Health System: "Clinical Utility to the Clinician"
  • Stephen P. Welby, U.S. Department of Defense: "DOD's Value Engineering Initiative"

One of the conference's highlights was presentation by students of real-world Value-driven Engineering project, including:

  • A team of students from Johns Hopkins University Center for Bioengineering Innovation and Design, who won the conference grand prize for case studies, created an ultraportable, easy-to-use fetal heart rate monitor. Every year, approximately 1 million stillbirths occur and nearly 99% of these newborn deaths are in developing countries. One major cause is the lack of monitoring of the baby's status during labor. The student team's battery-powered device uses a portable microphone with a modified attachment and a smartphone to display fetal rates prior to delivery. Though Doppler monitoring devices have been proven to be more effective, they are not widely available due to their prohibitively high cost.

  • A team studying at Virginia Commonwealth University, who helped develop an easy to
    '/>"/>

Contact: Scott Rainone
srainone@abiakron.org
330-572-7581
Austen BioInnovation Institute in Akron
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. American College of Medical Genetics receives $13.5M NIH contract
2. Researchers design artificial cells that could power medical implants
3. Salk scientist Fred H. Gage to receive the Keio Medical Science Prize
4. New book dissects statistics for doctors and medical students
5. Supercomputer provides massive computational boost to biomedical research at TGen
6. A card-swipe for medical tests
7. Rhode Island Hospital simulation center examines benefits and applications of medical simulation
8. Case Western Reserve receives Ellison Medical Foundation New Scholar in Aging award
9. NC State finds new nanomaterial could be breakthrough for implantable medical devices
10. TECNALIA investigates advanced biomaterials to make more reliable and hardwearing medical implants
11. New book helps medical students master clinical skills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... new University of Central Florida study will examine how rising ... Florida Panhandle and Alabama and Mississippi coasts. The research, ... Engineering, is a response to scientific studies that show sea ... research also could potentially be linked with models of how ...
... German . An international team of researchers, including ... San Francisco (USA) and Dr. Shannon McPherron of the Max ... evidence that human ancestors were using stone tools and consuming ... earlier than previously documented. While working in the Afar region ...
... mantle reservoir on Baffin Island in the Canadian Arctic. Geologist ... the finding--the first discovery of what may be a primitive ... The Earth,s mantle is a rocky, solid shell that is ... up about 84 percent of the Earth,s volume. The mantle ...
Cached Biology News:Study to examine rising sea level's impact on estuaries, coastal communities 2Scientists discover oldest evidence of human stone tool use and meat-eating 2Scientists discover oldest evidence of human stone tool use and meat-eating 3Scientists discover oldest evidence of human stone tool use and meat-eating 4Oldest Earth mantle reservoir discovered 2
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30
... June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ... products in China , said today that it has become the ... Penlon, a UK firm specializing in anesthesia and breathing equipment for 60,years. ... ...
... CITY, Kan. , June 1 Oncimmune ... test that aids physicians in risk assessment and the ... results demonstrating the diagnostic and economic benefits of a ... significantly improve the prognosis for lung cancer patients. Currently, ...
... ... eLadder® Safety course series into its curriculum. The online drug safety training courses ... to enrolled PharmD and PhD students, postdoctoral fellows, and residents via the University of ... ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 2Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 3Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 5Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 6Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 7University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: